(Q52023434)

20 April 2018

title

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis (English)

1 reference

20 April 2018

0 references

1

1 reference

20 April 2018

author name string

Leist T

series ordinal

2

1 reference

20 April 2018

Bielekova B

series ordinal

3

1 reference

20 April 2018

McFarland HF

series ordinal

4

1 reference

20 April 2018

publication date

1 November 2000

1 reference

20 April 2018

Journal of Neuroimmunology

published in

1 reference

20 April 2018

volume

111

1 reference

20 April 2018

issue

1-2

1 reference

20 April 2018

page(s)

186-194

1 reference

20 April 2018

VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Regulatory mechanisms in leukocyte adhesion: flexible receptors for sophisticated travelers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Lymphocyte interactions with endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900362-3

7 January 2021

10.1016/S0165-5728(00)00362-3

Identifiers

DOI

1 reference

20 April 2018

1 reference

20 April 2018